BPK 143 Study Guide - Midterm Guide: Mechanical Efficiency, Hemoglobin, Blood Doping

172 views3 pages

amethystworm242

13 Oct 2011

School

Simon Fraser University

Department

Biomedical Physio & Kines

Course

BPK 143

Professor

Tony Leyland

For unlimited access to Study Guides, a Grade+ subscription is required.

Document Summary

Study questions: compare the results of the rockport walking test and the 1. 5-mile run test. 1. 5 mile test is more strenuous because intensity is higher: you will raise your hr higher for 1. 5 mile run test, choose an ergogenic aid that is reported to improve aerobic power. It could be one of those mentioned in the study guide or a different one. Explain: no, it is minimally benefiecial, hemoglobin in blood is already almost fully saturated with oxygen. Partial pressure of oxygen in the air would be increased so there may be very minimal benefit: a 25-year-old man has been on an aerobic conditioning program for the past six months. During that time, his maximum oxygen uptake and running performance have been continuously improving. For the next few months, he will be quite busy and he won"t have as much time to train, but he wants to maintain his current aerobic fitness level.

Related Questions

Why is my IV green?

Solubility is a property of mixtures with far reaching effects in biology, medicine, and other technical fields. Research the causes and effects of IV (intravenous) drug incompatibility and answer the following questions. Be sure to reference the solubility rules on pages 336 and 337 of the book during your research and while answering the questions. Back up your responses with your sources.

1.)What are some of the causes of IV drug incompatibility and what can their results be?

2.)Nitrates, sulfates, chlorides, and phosphates are common ions used in medicine. Based on the solubility rules, would you expect to have any drug incompatibilities from mixing these ions with any metal ions relevant to biology or medicine? Why or why not?

3.)Do you think the principles behind IV drug incompatibility can also be applied to other applications or modes of drug delivery? If so, what kind of applications could it be applied to? If not, why not?

4.)How does solubility and/or drug incompatibility relate to your intended profession? Are there particular problems that could arise if you didn't check?

5.)Respond to one additional studentâs answer to question 4 and discuss similarities and differences between your professions and risks.

A 30-year-old white man saw his family physician because of increasing fatigue over the previous few months. Physical examination revealed a pale but otherwise normal-appearing adult, although the liver and spleen to be very slightly enlarged. The patient reported that his first urine of the morning was occasionally dark brown. His physician ordered as CBC, urinalysis, and liver and spleen scan:

Parameter	Result	Reference Range
Hemoglobin	8.5 g/dL	14-18 g/dL
Hematocrit	25%	42-52%
RBC	2.6 x 10¹²/L	4.5-5.5 x 10¹²/L
WBC	4.4 x 10⁹/L	4.5-11.0 x 10⁹/L

The differential count revealed an increase in lymphocytes (60%), but the percentages of other leukocytes were within the normal range. The urine demonstrated the presence of hemosiderin. Serum iron level and reticulocyte counts were additionally requested. The total serum iron was decreased, and the reticulocyte count was increased to 13%

Questions

Based on the patient history and the laboratory results provided, what is the most likely cause for anemia in this patient?

What kind of erythrocyte morphology would you expect to observe in the peripheral blood of this patient?

What laboratory tests should be performed to confirm the diagnosis? How are they performed and what are the expected results?

What is the appropriate treatment for this disorder?

Define antibody screen and antibody identification.

2. Differentiate between the importance and use of the antibody screen versus antibody identification regarding each of the following:
a. Potential blood recipient
b. Donor unit
c. Prenatal/Postpartum patients
d. Recently transfused patients with positive DAT (Direct Antiglobulin Test)
e. Neonate with positive DAT

3. State the three phases of testing used in the antibody screen or antibody identification and which type of antibody can be detected in each phase.

4. State the significance of a negative antibody screen.

5. State the significance of a positive antibody screen.

6. Explain the importance of obtaining a patient transfusion and medication history when investigating a positive antibody screen.

7. Given the type of antibody identified, determine the necessary procedure for compatibility testing to provide blood for transfusion for the patient.

8. Explain the purpose of the autocontrol and its relationship to the DAT.

9. Define dosage as it relates to antibody-antigen interactions.

10. Given specific red cell antigen expression, determine if the antigen expression is homozygous or heterozygous.

11. Explain the significance of using screening and panel cells with homozygous antigen expression when performing an antibody screen or identification.

12. Explain the â3 cell rule-inâ rule with regard to antibody identification for single or multiple antibodies present.

13. Explain the ârule-outsâ rule with regard to antibody identification.

14. Given antibody agglutination results for an antibody identification panel, perform the â3 cell rule-inâ and all ârule-outsâ to identify the antibody(ies) present.

15. State which blood group antigens are destroyed by enzyme treatment and which antibodies have enhanced expression when tested against enzyme treated reagent red blood cells.

16. Define mixed field agglutination.

17. Describe specific occasions when mixed field agglutination may be present and identified.

18. Given a patient history, current ABO/Rh type, antibody screening and (if applicable) antibody identification results, interpret the testing results.

19. Given a patient history, current ABO/Rh type, antibody screening and (if applicable) antibody identification results, select the appropriate ABO/Rh type of red cell products for transfusion.

20. Given a patient history, current ABO/Rh type, antibody screening and (if applicable) antibody identification results, select the appropriate ABO type of frozen component products for transfusion.

21. Given a patient history, current ABO/Rh type, antibody screening and current or historical antibody identification results, determine the appropriate red blood cell antigen negative blood that would be required for transfusion.

22. For patients in Objective #21, given the antigen frequency of those red blood cell antigens, calculate the number of red blood cell donor units that would need to be screened for transfusion to fulfill the order requested by the physician.

23. Given a patientâs ABO/Rh type and/or other red blood cell antigen phenotyping results, determine the most probable genotype of the patient.

24. Given a patientâs ABO/Rh type and/or other red blood cell antigen phenotyping results, determine the most probable genotype or phenotype of the patientâs parents.

25. Given a patientâs ABO/Rh type and/or other red blood cell antigen phenotyping results, determine the antibody(ies) present in the patientâs serum or plasma.

26. Given donor physical, screening and/or history results, determine if the donor would be accepted, temporarily deferred, or permanently deferred from donating blood products

BPK 143 Study Guide - Midterm Guide: Mechanical Efficiency, Hemoglobin, Blood Doping

Document Summary

Get access

Related Documents

BPK 143 Study Guide - Midterm Guide: Performance-Enhancing Substance, Aerobic Conditioning, Croatian Radiotelevision

BPK 143 Chapter Notes - Chapter 5: Myoglobin, Performance-Enhancing Substance, Erythropoietin

BPK 143 Chapter Notes - Chapter 5: Hematocrit, Circulatory System, Blood Doping

Related Questions